Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Fin

14.10.2022 - - Enzo Life Sciences reports revenue of $32.6 million and 8% growth in FY 2022, net of FX - Company successfully launched AMPIVIEW gene expression platform powered by LoopRNA ISH technology - Continues to engage with ...

Related Keywords

New York , United States , Farmingdale , Long Island , Enzo Loop , Matthew Kupferberg , Lynn Granito , Chris Calabrese , Hamid Erfanian , Enzo Biochem , Lifesci Advisors , Linkedin , Enzo Clinical Lab , Enzo Life Sciences , Company Form , Enzo Clinical Laboratory , Berry Company Public Relations , York State Department Of Health , Enzo Biochem Inc , Securities Exchange , United States Centers For Disease , Paycheck Protection Program , Lab Developed , Enzo Diagnostics , Emergency Use , United States Centers , Disease Control , General Counsel , New York State Department , Ann Arbor , Life Sciences , Clinical Lab , Eastern Standard Time , Investor Relations , Sarbanes Oxley Act , Securities Act , Securities Exchange Act , Risk Factors , Sci Advisors , Protection Program , Shares Outstanding ,